Sunosi (solriamfetol)

About Axsome Therapeutics

Axsome Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for central nervous system (CNS) disorders. Founded in 2012, the company has transitioned from a development-focused entity to a revenue-generating commercial organization with three FDA-approved products: Auvelity (AXS-05) for MDD, Sunosi for narcolepsy/OSA, and Symbravo for migraine. Its core strategy leverages a differentiated platform focused on synergistic drug combinations and novel formulations to address significant unmet needs in psychiatry, neurology, and pain, driving a market valuation exceeding $8 billion.

About Axsome Therapeutics

Axsome Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for central nervous system (CNS) disorders. Founded in 2012, the company has transitioned from a development-focused entity to a revenue-generating commercial organization with three FDA-approved products: Auvelity (AXS-05) for MDD, Sunosi for narcolepsy/OSA, and Symbravo for migraine. Its core strategy leverages a differentiated platform focused on synergistic drug combinations and novel formulations to address significant unmet needs in psychiatry, neurology, and pain, driving a market valuation exceeding $8 billion.

Therapeutic Areas